RANTES was also proposed earlier to be considered as a biomarker for disease progression in stage IIA breast cancer patients [75] and currently, is being suggested as an inflammatory mediator with pro-malignancy activities in breast cancer [76]. This evidence concerns the gene CCL5 and breast cancer.